Septerna, Inc. (SEPN)
38.79
-0.34
(-0.87%)
USD |
NASDAQ |
Oct 01, 14:31
Septerna Enterprise Value : 1.437B for Sept. 30, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 30, 2026 | 1.437B |
| September 29, 2026 | 1.437B |
| September 28, 2026 | 1.465B |
| September 25, 2026 | 1.375B |
| September 24, 2026 | 1.392B |
| September 23, 2026 | 1.406B |
| September 22, 2026 | 1.494B |
| September 21, 2026 | 1.410B |
| September 18, 2026 | 1.417B |
| September 17, 2026 | 1.454B |
| September 16, 2026 | 1.406B |
| September 15, 2026 | 1.425B |
| September 14, 2026 | 1.456B |
| September 11, 2026 | 1.409B |
| September 10, 2026 | 1.374B |
| September 09, 2026 | 1.384B |
| September 08, 2026 | 1.357B |
| September 04, 2026 | 1.329B |
| September 03, 2026 | 1.331B |
| September 02, 2026 | 1.363B |
| September 01, 2026 | 1.371B |
| August 31, 2026 | 1.392B |
| August 28, 2026 | 1.427B |
| August 27, 2026 | 1.498B |
| August 26, 2026 | 1.488B |
| Date | Value |
|---|---|
| August 25, 2026 | 1.536B |
| August 24, 2026 | 1.501B |
| August 21, 2026 | 1.477B |
| August 20, 2026 | 1.513B |
| August 19, 2026 | 1.656B |
| August 18, 2026 | 1.650B |
| August 17, 2026 | 1.669B |
| August 14, 2026 | 1.682B |
| August 13, 2026 | 1.712B |
| August 12, 2026 | 1.851B |
| August 11, 2026 | 1.831B |
| August 10, 2026 | 1.424B |
| August 07, 2026 | 1.423B |
| August 06, 2026 | 1.455B |
| August 05, 2026 | 1.420B |
| August 04, 2026 | 1.430B |
| August 03, 2026 | 1.248B |
| July 31, 2026 | 1.223B |
| July 30, 2026 | 1.257B |
| July 29, 2026 | 1.185B |
| July 28, 2026 | 1.202B |
| July 27, 2026 | 1.180B |
| July 24, 2026 | 1.162B |
| July 23, 2026 | 1.179B |
| July 22, 2026 | 1.212B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Cocrystal Pharma, Inc. | 14.95M |
| CNBX Pharmaceuticals, Inc. | 1.305M |
| GB Sciences, Inc. | -- |
| Arvinas, Inc. | -54.60M |
| Fulcrum Therapeutics, Inc. | -31.31M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -13.03M |
| Revenue (Quarterly) | 26.75M |
| Total Expenses (Quarterly) | 39.78M |
| EPS Diluted (Quarterly) | -0.2894 |
| Gross Profit Margin (Quarterly) | 98.40% |
| Profit Margin (Quarterly) | -48.73% |
| Earnings Yield | -1.40% |
| Normalized Earnings Yield | -1.402 |